-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in RH therapeutics. - GlobalData epidemiologists estimated more than 79 million diagnosed prevalent cases of RH in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for RH. - The marketed drugs space for RH is dominated by off-label antihypertensive therapies. - The R&D activity is limited within the RH space, with only three molecules present in the late-stage pipeline.. - The US is emerging as...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics. - More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PAD. - The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others. - The PAD pipeline mainly includes receptor agonists, followed by biological factor activators...
-
Product Insights
Atherosclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Atherosclerosis - Drugs In Development, 2023’, provides an overview of the Atherosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ischemia Reperfusion Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drugs In Development, 2023’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Idiopathic (Essential) Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Drugs In Development, 2023’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drugs In Development, 2023’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Occlusive Arterial Disease (OAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Occlusive Arterial Disease (OAD) - Drugs In Development, 2023’, provides an overview of the Occlusive Arterial Disease (OAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Artery Occlusive Disease (PAOD) - Drugs In Development, 2023’, provides an overview of the Peripheral Artery Occlusive Disease (PAOD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Artery Occlusive Disease (PAOD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Diastolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Diastolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Diastolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...